Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Temporal Dynamics of Tumor-Microenvironment Interaction and Treatment Responses Revealed through Time-Lapse Compartment-Specific Bioluminescence Imaging: Translational implications

Eugen Dhimolea, PhD, Emily King, Efstathios Kastritis, MD, Douglas W. McMillin, PhD, Jake E. Delmore, B.Sc., Joseph M. Negri, B.Sc., Hannah M. Jacobs, B.Sc., Catriona A. Hayes, MD, Michal Sheffer, PhD, Yiguo Hu, PhD, Subhashis Sarkar, PhD, Richard W.J. Groen, PhD, Megan A. Bariteau, B.Sc., Blake T. Aftab, PhD, Constantine S. Mitsiades, MD PhD

Blood (2014) 124 (21): 276.

https://doi.org/10.1182/blood.V124.21.276.276

Published: 2014

Journal Articles

Cell Non-Autonomous Modulation Of Tumor Cell Responses To Pharmacological Inhibition Of The Proteasome

Eugen Dhimolea, PhD, Richard W.J. Groen, PhD, Catriona A. Hayes, MD, Jana Jakubikova, PhD, Bariteau Megan, Jake E. Delmore, Hannah M. Jacobs, Julio-Cesar Marin, Gregory Della Penna, Douglas W. McMillin, PhD, Ana Acuna, Panisinee Lawasut, MD, Nancy Kohl, PhD, Constantine S. Mitsiades, MD, PhD

Blood (2013) 122 (21): 4454.

https://doi.org/10.1182/blood.V122.21.4454.4454

Published: 2013

Journal Articles

Accessory Cells From Diverse Tissue Microenvironments Alter Tumor Cell Responses to Multitargeted Kinase Inhibitors: Therapeutic Implications From a Large-Scale Systematic Evaluation.

Ana Acuña-Villaorduña, MD, Douglas W. McMillin, PhD, Constantine S. Mitsiades, MD, PhD

Blood (2012) 120 (21): 2469.

https://doi.org/10.1182/blood.V120.21.2469.2469

Published: 2012

Journal Articles

Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents

Catriona A. Hayes, MD, Paul Dowling, PhD, Richard W.J. Groen, PhD, Douglas W. McMillin, PhD, Jake E. Delmore, Hannah M. Jacobs, Niels W.C.J. van de Donk, MD, PhD, Eugen Dhimolea, PhD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Martin Clynes, PhD, Peter O'Gorman, M.D., Constantine S. Mitsiades, MD, PhD

Blood (2012) 120 (21): 3995.

https://doi.org/10.1182/blood.V120.21.3995.3995

Published: 2012

Journal Articles

Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function

Douglas W. McMillin, Jake Delmore, Joseph M. Negri, Matthew Vanneman, Shohei Koyama, Robert L. Schlossman, Nikhil C. Munshi, Jacob Laubach, Paul G. Richardson, Glenn Dranoff, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2012) 119 (15): e131–e138.

https://doi.org/10.1182/blood-2011-04-348490

Published: 2012

Includes: Supplemental data

Journal Articles

Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma

Sun-Young Kong, MD, PhD, Yosef Landesman, PhD, Jana Jakubikova, PhD, Michael A. Sellitto, Antonia Cagnetta, MD, Michele Cea, MD, Michelle C. Chen, Francesca Cottini, MD, Douglas W. McMillin, PhD, Chirag Acharya, MD, William Senapedis, PhD, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Dilara McCauley, PhD, Jean-Richard Saint-Martin, BS, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2011) 118 (21): 2913.

https://doi.org/10.1182/blood.V118.21.2913.2913

Published: 2011

Journal Articles

In Vitro Anti-Myeloma Activity of the Multitargeted Kinase Inhibitor Midostaurin in the Context of Heterotypic Cocultures of Myeloma Cells with Nonmalignant Microenvironmental Accessory Cells

Panisinee Lawasut, MD, Hannah M. Jacobs, Jake E Delmore, Joseph Negri, Douglas W. McMillin, PhD, Ellen L Weisberg, Ph.D., James D. Griffin, MD, Paul G. Richardson, MD, Kenneth C Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2011) 118 (21): 2923.

https://doi.org/10.1182/blood.V118.21.2923.2923

Published: 2011

Journal Articles

Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance

*Catriona A. Hayes, MD, *Paul Dowling, PhD, Joseph Negri, Michael Henry, Leutz Buon, Jana Jakubikova, PhD, Jake E Delmore, Douglas W. McMillin, PhD, Steffen Klippel, PhD, Hannah M. Jacobs, Niels W.C.J. van de Donk, MD, PhD, Eugen Dhimolea, PhD, Panisinee Lawasut, MD, MSc, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Martin Clynes, PhD, *Peter O Gorman, MD, PhD, *Constantine S. Mitsiades, MD, PhD

Blood (2011) 118 (21): 1820.

https://doi.org/10.1182/blood.V118.21.1820.1820

Published: 2011

Journal Articles

Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing

Niels W.C.J. van de Donk, MD, PhD, Henk M. Lokhorst, MD, Maarten Emmelot, Tineke Aarts-Riemens, Douglas W. McMillin, PhD, Gullu Gorgun, PhD, Steffen Klippel, PhD, Eugen Dhimolea, PhD, Jana Jakubikova, PhD, Catriona A. Hayes, MD, Panisinee Lawasut, MD, Jake E Delmore, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 1838.

https://doi.org/10.1182/blood.V118.21.1838.1838

Published: 2011

Journal Articles

Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor – Microenvironment Interactions.

Efstathios Kastritis, Jana Jakubikova, Jake Delmore, Steffen Klippel, Douglas W. McMillin, Melissa Ooi, Hannah M. Jacobs, Jacob P. Laubach, Paul G Richardson, Kenneth C. Anderson, Andrew L. Kung, Constantine S. Mitsiades, MD, PhD

Blood (2010) 116 (21): 1574.

https://doi.org/10.1182/blood.V116.21.1574.1574

Published: 2010

Journal Articles

Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function

Douglas W. McMillin, Jake Delmore, Matthew W. Vanneman, Robert L. Schlossman, MD, John Feather, Nikhil C. Munshi, Jacob P. Laubach, Paul G Richardson, Glenn Dranoff, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2010) 116 (21): 451.

https://doi.org/10.1182/blood.V116.21.451.451

Published: 2010

Journal Articles

MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenström's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors

Douglas W. McMillin, Zachary Hunter, Jake Delmore, Val Monrose, Peter G Smith, Ann Birner, Paul G Richardson, Kenneth C. Anderson, Steven P. Treon, Andrew L. Kung, Constantine S. Mitsiades

Blood (2010) 116 (21): 2988.

https://doi.org/10.1182/blood.V116.21.2988.2988

Published: 2010

Journal Articles

Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies

Richard J. Rickles, Laura T. Pierce, Thomas P. Giordano, 3rd, Winnie F. Tam, Douglas W. McMillin, Jake Delmore, Jacob P. Laubach, Alexis A. Borisy, Paul G. Richardson, Margaret S. Lee

Blood (2010) 116 (4): 593–602.

https://doi.org/10.1182/blood-2009-11-252668

Published: 2010

Includes: Supplemental data

Journal Articles

Activity of Plk Inhibitor BI2536 on Myeloma Cells

Douglas W. McMillin, PhD, Joseph Negri, Jake Delmore, Melissa G. Ooi, MD, Jana Jakubikova, Renee Wright, Nathanael Gray, PhD, Andrew Kung, MD, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2008) 112 (11): 2764.

https://doi.org/10.1182/blood.V112.11.2764.2764

Published: 2008

Journal Articles

Preclinical Evaluation of CRx-501, a Potent Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma

Richard J Rickles, Ph.D., Laura Pierce, Thomas Giordano, William Avery, Melissa Farwell, David Crowe, Winnie F. Tam, Ph.D., Mei Chen, Ph.D., Vikram Kansra, PhD, Douglas W. McMillin, BSc, PhD, Kenneth C Anderson, MD, Constantine Mitsiades, M.D., Ph.D., Margaret S. Lee, PhD

Blood (2008) 112 (11): 252.

https://doi.org/10.1182/blood.V112.11.252.252

Published: 2008

Journal Articles

Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib

Melissa G. Ooi, Patrick J. Hayden, Douglas W. McMillin, Joseph M. Negri, Jake Delmore, Noopur S Raje, Nikhil C. Munshi, Dharminder Chauhan, Teru Hideshima, Paul G. Richardson, Constantine S. Mitsiades, Kenneth C Anderson, Nicholas Mitsiades

Blood (2008) 112 (11): 2651.

https://doi.org/10.1182/blood.V112.11.2651.2651

Published: 2008

Journal Articles

The Antidiabetic Biguanide Metformin Induces Growth Arrest in Multiple Myeloma Cells in Vitro, overcoming the Effect of Stromal Cells

Melissa G. Ooi, Douglas W. McMillin, Joseph M. Negri, Jake Delmore, Nikhil C. Munshi, Dharminder Chauhan, Teru Hideshima, Paul G. Richardson, Constantine S. Mitsiades, Kenneth C. Anderson, Nicholas Mitsiades

Blood (2008) 112 (11): 2652.

https://doi.org/10.1182/blood.V112.11.2652.2652

Published: 2008

Journal Articles

Synergistic Activity of Adenosine A2A and Beta-2 Adrenergic Receptor Agonists in Myeloma Cells in the Context of Tumor-Stromal Interactions

Douglas W. McMillin, PhD, Richard Rickles, Joseph Negri, Jake Delmore, Melissa G. Ooi, MD, Melissa Farwell, David Crowe, Mei Chen, William Avery, Vikram Kansra, PhD, Kenneth C. Anderson, MD, Margaret S. Lee, PhD, Constantine S. Mitsiades, MD, PhD

Blood (2008) 112 (11): 2663.

https://doi.org/10.1182/blood.V112.11.2663.2663

Published: 2008

Journal Articles

Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics

Melissa G. Ooi, Douglas W. McMillin, Joseph M. Negri, Jake Delmore, Steffen Klippel, Nicholas Mitsiades, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2008) 112 (11): 219.

https://doi.org/10.1182/blood.V112.11.219.219

Published: 2008

Journal Articles

Adenosine A2A Receptor Agonism and PDE Inhibition: A Synergistic Multi-Target Mechanism Discovered through Systematic Combination Screening in Multiple Myeloma

Richard J Rickles, Ph.D., Laura Pierce, Thomas Giordano, Winnie F. Tam, Ph.D., Douglas W. McMillin, BSc, PhD, Kenneth C. Anderson, MD, Constantine Mitsiades, M.D., Ph.D., Margaret S Lee, Ph.D

Blood (2008) 112 (11): 847.

https://doi.org/10.1182/blood.V112.11.847.847

Published: 2008

NARROW

Temporal Dynamics of Tumor-Microenvironment Interaction and Treatment Responses Revealed through Time-Lapse Compartment-Specific Bioluminescence Imaging: Translational implications

Cell Non-Autonomous Modulation Of Tumor Cell Responses To Pharmacological Inhibition Of The Proteasome

Accessory Cells From Diverse Tissue Microenvironments Alter Tumor Cell Responses to Multitargeted Kinase Inhibitors: Therapeutic Implications From a Large-Scale Systematic Evaluation.

Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents

Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function

Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma

In Vitro Anti-Myeloma Activity of the Multitargeted Kinase Inhibitor Midostaurin in the Context of Heterotypic Cocultures of Myeloma Cells with Nonmalignant Microenvironmental Accessory Cells

Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance

Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing

Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor – Microenvironment Interactions.

Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function

MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenström's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors

Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies

Activity of Plk Inhibitor BI2536 on Myeloma Cells

Preclinical Evaluation of CRx-501, a Potent Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma

Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib

The Antidiabetic Biguanide Metformin Induces Growth Arrest in Multiple Myeloma Cells in Vitro, overcoming the Effect of Stromal Cells

Synergistic Activity of Adenosine A2A and Beta-2 Adrenergic Receptor Agonists in Myeloma Cells in the Context of Tumor-Stromal Interactions

Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics

Adenosine A2A Receptor Agonism and PDE Inhibition: A Synergistic Multi-Target Mechanism Discovered through Systematic Combination Screening in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only